Research Article

Multiple Control Strategies for Prevention of Avian Influenza Pandemic

Roman Ullah,^{1,2} Gul Zaman,³ and Saeed Islam²

¹ Department of Mathematics, Bacha Khan University, Charsadda 24420, Pakistan

² Department of Mathematics, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan

³ Department of Mathematics, University of Malakand, Chakdara 23101, Pakistan

Correspondence should be addressed to Roman Ullah; romanullah@yahoo.com

Received 28 August 2013; Accepted 31 December 2013; Published 24 February 2014

Academic Editors: P. Crooke and G. Fedele

Copyright © 2014 Roman Ullah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We present the prevention of avian influenza pandemic by adjusting multiple control functions in the human-to-human transmittable avian influenza model. First we show the existence of the optimal control problem; then by using both analytical and numerical techniques, we investigate the cost-effective control effects for the prevention of transmission of disease. To do this, we use three control functions, the effort to reduce the number of contacts with human infected with mutant avian influenza, the antiviral treatment of infected individuals, and the effort to reduce the number of infected birds. We completely characterized the optimal control and compute numerical solution of the optimality system by using an iterative method.

1. Introduction

Highly pathogenic avian influenza is a zoonotic disease caused by H5N1 virus and it has a devastating impact on poultry causing above 90 percent mortality within 48 hours of infection [1]. The disease also spreads to humans through the direct contact with the infected poultry. Despite all advances of medical, avian influenza still poses a significant threat to health and economy of the society. The laboratory confirmed that the fatality rate in human case is about 60 percent [2].

Several reports have so far been made of possible coinfection of humans with an H5N1 strain and a human strain [3, 4]. One of the coinfection reports is of a Turkish family cluster. In late December 2005 and early January 2006, a cluster of 8 confirmed highly pathogenic avian influenza (H5N1) cases was detected in Dogubayazit district in eastern Turkey [5]. All confirmed case patients were hospitalized after onset of symptoms. Four of them were died and the other four recovered. Another cluster of 8 cases of HPAI (H5N1) was detected in the village of Kubu Sambalang, Samatra, Indonesia, in April-May 2006 [6]. Only one of them recovered and the remaining seven members died. Though

the human-to-human transmission of the disease is rare, its potential to change into an extremely high virulent human-to-human transmittable pandemic strain is the real danger to human health. Due to this threat, some international organizations have developed and began to implement different strategies (biosecurity, isolation, and antiviral treatment) for forestalling the onset of a pandemic. It has been estimated that a future avian influenza pandemic could cause hundreds of billions of dollars due to lost productivity, associated medical policies, and prevention policies.

Mathematical models have been widely used to evaluate the effects of control measures of avian influenza [7–9]. In 2007, Iwami et al. [10] proposed a mathematical model of the spread of avian influenza from bird population to human population. They discussed that to minimize the spread of the disease in human population, we must take the measures for the infected human with bird flu to quarantine when mutant bird flu has already occurred. Lee et al. [11] show that the optimal control strategies that rely on the use of antiviral treatment or isolation strategies can reduce the number of clinical cases; therein they emphasize isolation strategies in mitigation of pandemic of influenza particularly

when the access to antiviral resources is limited. Later on Ullah et al. [12] proposed the control strategies where they focus on minimizing the impact of influenza by minimizing the vaccine wanning.

In this paper, we focus on identifying the optimal control strategies for the model developed in [13]; these controls minimize the impact of avian influenza by isolating the infected individuals, the judicious use of drug supply, and eliminating the infected birds. Recommended medicines like oseltamivir or zanamivir must be taken within two days after the appearance of symptoms. The clinically ill and infectious individuals can be isolated by reasonably effective ways to reduce the transmission of disease, like to educate them to cover their sneeze and cough, not to spit openly, and to avoid the closed contacts with others, sanitizing the rooms or equipments occupied by the patients. The diagnosed infected birds should be culled within a few hours and all the infected dead birds and other contaminated objects (faeces, blood, and feathers) must be destroyed properly (burying, incineration) as soon as possible. We can get the most effective results if we use the isolation, treatment of clinically infectious humans, and elimination of infected birds concurrently.

2. Model Frame Work

In this section, the compartmental model that divides the human and birds populations into two different classes presents the optimal control problem for the transmission dynamics of avian influenza. Our main aim is to show that it is possible to implement the time-dependent antiavian influenza control techniques while minimizing the cost of such measures. In order to do this, we introduce three time-dependent control functions u_1 , u_2 , and u_3 . The control u_1 represents the effort to reduce the number of contacts with human infected by mutant avian influenza, u_2 represents the fraction of clinically infectious cases treated with antiviral per unit of time, and u_3 is the effort to reduce the number of infected birds. Note that the controls are fully effective when $u_i = 1$ for $i = 1, 2, 3$, while there is no control if $u_i = 0$. We divide the total human population at time t denoted by N_h into five distinct epidemiological subclasses which are susceptible X_h , exposed E_h , clinically ill and infectious I_h , treated T_h , and recovered R_h and the birds population N_b into three distinct subclasses which are susceptible X_b , exposed E_b , and infected I_b . Taking into account the assumptions above, the dynamics of the control problem is given by

$$\begin{aligned}\frac{dX_h}{dt} &= \Lambda - \mu_h X_h - (1 - u_1) \alpha_1 X_h I_h - \alpha_2 X_h I_b + \epsilon_h R_h, \\ \frac{dE_h}{dt} &= (1 - u_1) \alpha_1 X_h I_h + \alpha_2 X_h I_b - (\mu_h + \phi_h) E_h, \\ \frac{dI_h}{dt} &= \phi_h E_h - (\rho_h + \beta_h + \mu_h + u_2) I_h, \\ \frac{dT_h}{dt} &= \rho_h I_h - (\gamma_h + \mu_h) T_h, \\ \frac{dR_h}{dt} &= \gamma_h T_h + u_2 I_h - (\mu_h + \epsilon_h) R_h,\end{aligned}$$

$$\begin{aligned}\frac{dX_b}{dt} &= \pi - \mu_b X_b - (1 - u_3) \alpha_3 X_b I_b, \\ \frac{dE_b}{dt} &= (1 - u_3) \alpha_3 X_b I_b - (\mu_b + \phi_b) E_b, \\ \frac{dI_b}{dt} &= \phi_b E_b - (\beta_b + \mu_b) I_b,\end{aligned}$$

(1)

with the initial conditions

$$\begin{aligned}X_h(0) &\geq 0, \quad E_h(0) \geq 0, \quad I_h(0) \geq 0, \\ T_h(0) &\geq 0, \quad R_h(0) \geq 0, \quad X_b(0) \geq 0, \\ E_b(0) &\geq 0, \quad I_b(0) \geq 0.\end{aligned}$$

(2)

The human population is recruited at a constant birth rate Λ , ϵ_h is the rate of immunity loss, ϕ_h is the progression rate from E_h to I_h , ρ_h represents the treatment rate of human, μ_h and μ_b are the natural death rates of humans and birds, respectively, β_h and β_b are disease induced death rates in humans and birds, respectively, π represents recruitment rate of birds population, γ_h shows recovery due to treatment, ϕ_b is progression rate of birds from E_b to I_b , and α_1 , α_2 , and α_3 are effective contact rates between X_h and I_h , X_h and I_b , and X_b and I_b , respectively.

The objective of our control problem is to minimize the number of clinically infectious humans and infected birds and the cost of implementing the control by using possible minimal control variables $u_i(t)$ for $i = 1, 2, 3$. We use the Lebesgue measurable control and define our objective functional as

$$\begin{aligned}J(u_1, u_2, u_3) &= \int_0^{t_{\text{end}}} \left(A_1 I_h + A_2 I_b + \frac{1}{2} (C_1 u_1^2 + C_2 u_2^2 + C_3 u_3^2) \right) dt,\end{aligned}$$

(3)

where A_1 and A_2 are positive constants to keep a balance in the size of I_h and I_b . The square of the control variables reflects the severity of the side effects of the controls. C_1 , C_2 , and C_3 are positive weight parameters such that $0 < C_1 < \Lambda/\mu_h$, $0 < C_2 < \Lambda/\mu_h$, and $0 < C_3 < \pi/\mu_b$. The objective of the optimal control problem is to seek optimal control functions $(u_1^*(t), u_2^*(t), u_3^*(t))$ such that

$$J(u_1^*, u_2^*, u_3^*) = \min_{(u_1, u_2, u_3) \in U} \{J(u_1, u_2, u_3) \mid (u_1, u_2, u_3) \in U\},$$

(4)

where the control set is defined as

$$U = \{u = (u_1, u_2, u_3) \mid u_i \text{ is Lebesgue measurable on } [0, 1],$$

$$0 \leq u_i(t) \leq 1, t \in [0, t_{\text{end}}], \text{ for } i = 1, 2, 3\},$$

(5)

subject to the system (2) with appropriate initial conditions. Pontryagin's maximum principle [14] is used to solve this optimal control problem and the derivation of the necessary conditions. First we prove the existence of an optimal control for the system (2) and then derive the optimality system.

3. Existence of Control Problem

In this section, we consider the control system (2) with initial conditions at $t = 0$ to show the existence of the control problem. Note that, for the bounded Lebesgue measurable controls and nonnegative initial conditions, nonnegative

bounded solutions to the state system exist (see [15]). To prove the existence of the solution of system (2), we can write

$$Y_t = BY + F(Y), \quad (6)$$

where

$$Y = \begin{bmatrix} X_h \\ E_h \\ I_h \\ T_h \\ R_h \\ X_b \\ E_b \\ I_b \end{bmatrix}, \quad F(Y) = \begin{bmatrix} \Lambda - (1-u_1)\alpha_1 X_h I_h - \alpha_2 X_h I_b \\ (1-u_1)\alpha_1 X_h I_h + \alpha_2 X_h I_b \\ 0 \\ 0 \\ 0 \\ \pi - (1-u_3)\alpha_3 X_b I_b \\ (1-u_3)\alpha_3 X_b I_b \\ 0 \end{bmatrix}, \quad (7)$$

$$B = \begin{bmatrix} -\mu_h & 0 & 0 & 0 & \epsilon_h & 0 & 0 & 0 \\ 0 & -\mu_h - \phi_h & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & \phi_h & -\rho_h - \beta_h - \mu_h - u_2 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & \rho_h & -\gamma_h - \mu_h & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & \gamma_h + u_2 & -\mu_h - \epsilon_h & 0 & 0 & 0 \\ \mu_b & 0 & 0 & 0 & 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & -\mu_b - \phi_b & 0 \\ 0 & 0 & 0 & 0 & 0 & 0 & \phi_b & -\beta_b - \mu_b \end{bmatrix},$$

where Y_t denotes derivative of Y with respect to time t . Equation (3) is a nonlinear system with a bounded coefficient. We set

$$D(Y) = BY + F(Y). \quad (8)$$

Now,

$$F(Y_1) - F(Y_2) = \begin{bmatrix} (1-u_1)\alpha_1(X_{h2}I_{h2} - X_{h1}I_{h1}) + \alpha_2(X_{h2}I_{b2} - X_{h1}I_{b1}) \\ -(1-u_1)\alpha_1(X_{h2}I_{h2} - X_{h1}I_{h1}) - \alpha_2(X_{h2}I_{b2} - X_{h1}I_{b1}) \\ 0 \\ 0 \\ 0 \\ (1-u_3)\alpha_3(X_{b2}I_{b2} - X_{b1}I_{b1}) \\ -(1-u_3)\alpha_3(X_{b2}I_{b2} - X_{b1}I_{b1}) \\ 0 \end{bmatrix},$$

$$\begin{aligned} |F(Y_1) - F(Y_2)| &= |(1-u_1)\alpha_1(X_{h2}I_{h2} - X_{h1}I_{h1}) + \alpha_2(X_{h2}I_{b2} - X_{h1}I_{b1})| \\ &\quad + |(1-u_1)\alpha_1(X_{h2}I_{h2} - X_{h1}I_{h1}) + \alpha_2(X_{h2}I_{b2} - X_{h1}I_{b1})| \\ &\quad + |(1-u_3)\alpha_3(X_{b2}I_{b2} - X_{b1}I_{b1})| \\ &\quad + |(1-u_3)\alpha_3(X_{b2}I_{b2} - X_{b1}I_{b1})| \\ &\leq M[|X_{h2} - X_{h1}| + |I_{h2} - I_{h1}| + |X_{b2} - X_{b1}| + |I_{b2} - I_{b1}|], \end{aligned} \quad (9)$$

where

$$M = \max \left\{ 2 \left[(1-u_1)\alpha_1 \frac{\Lambda}{\mu_h} + \alpha_2 \frac{\pi}{\mu_b} \right], 2 \left[(1-u_3)\alpha_3 \frac{\pi}{\mu_b} + \alpha_2 \frac{\Lambda}{\mu_h} \right] \right\}. \quad (10)$$

Here the constant M is independent of the state variables X_h , I_h , R_h , X_b , and I_b . Also we get $|D(Y_1) - D(Y_2)| \leq V|Y_1 - Y_2|$, where $V = \max\{M, \|B\|\}$, which shows that D is uniformly Lipschitz continuous; hence by definition, the solution of the system exists (see [15]).

Let us go back to the optimal control problem (2)–(3). In order to find an optimal solution, first we should find the Lagrangian and Hamiltonian for the optimal control problem. The Lagrangian is

$$L = A_1 I_h + A_2 I_b + \frac{1}{2} (C_1 u_1^2 + C_2 u_2^2 + C_3 u_3^2). \quad (11)$$

We seek for the minimal value of the Lagrangian. To do this, we define the Hamiltonian H for the control problem, where λ_i , $i = 1, 2, \dots, 8$, are the adjoint variables:

$$\begin{aligned} H &= A_1 I_h + A_2 I_b + \frac{1}{2} (C_1 u_1^2 + C_2 u_2^2 + C_3 u_3^2) \\ &\quad + \lambda_1 [\Lambda - \mu_h X_h - (1-u_1)\alpha_1 X_h I_h - \alpha_2 X_h I_b + \epsilon_h R_h] \\ &\quad + \lambda_2 [(1-u_1)\alpha_1 X_h I_h + \alpha_2 X_h I_b - (\mu_h + \phi_h) E_h] \\ &\quad + \lambda_3 [\phi_h E_h - (\rho_h + \beta_h + \mu_h + u_2) I_h] \\ &\quad + \lambda_4 [\rho_h I_h - (\gamma_h + \mu_h) T_h] \end{aligned}$$

TABLE 1: Parameter values used for numerical simulations.

Notation	Parameters definition	Value
Λ	Recruitment rate of humans	1.7/day
α_1	Effective contact rate between X_h and I_h	0.3
α_2	Effective contact rate between X_h and I_b	0.15
α_3	Effective contact rate between X_b and I_b	0.12
π	Recruitment rate of birds	5/day
ϵ_h	Rate of immunity loss	0.005
μ_h	Natural death rate of humans	0.1/day
μ_b	Natural death rate of birds	0.3/day
γ_h	Recovery due to treatment	0.3
ρ_h	Treatment rate	0.75
β_h	Disease induced death rate in humans	0.4/day
β_b	Disease induced death rate in birds	3.7/day
ϕ_h	Progression rate from E_h to I_h	0.45
ϕ_b	Progression rate from E_b to I_b	0.85

$$\begin{aligned}
& + \lambda_5 [\gamma_h T_h + u_2 I_h - (\mu_h + \epsilon_h) R_h] \\
& + \lambda_6 [\pi - \mu_b X_b - (1 - u_3) \alpha_3 X_b I_b] \\
& + \lambda_7 [(1 - u_3) \alpha_3 X_b I_b - (\mu_b + \phi_b) E_b] \\
& + \lambda_8 [\phi_b E_b - (\beta_b + \mu_b) I_b].
\end{aligned} \tag{12}$$

For the existence of the control system (2), we state and prove the following theorem.

Theorem 1. *There exists an optimal control $u^* = (u_1^*, u_2^*, u_3^*) \in U$ such that*

$$J(u_1^*, u_2^*, u_3^*) = \min_{(u_1, u_2, u_3) \in U} J(u_1, u_2, u_3) \tag{13}$$

subject to the control system (2) with the initial conditions (2).

Proof. To prove the existence of an optimal control, we use the result in [16–18]. Note that the control and the state variables are non-negative values. In this minimizing problem, the necessary convexity of the objective functional in u_1, u_2 , and u_3 is satisfied. The set of all the control variables $(u_1, u_2, u_3) \in U$ is also convex and closed by definition. The optimal system is bounded which determines the compactness needed for the existence of an optimal control. In addition the integrand in the functional (3), $A_1 I_h + A_2 I_b + (1/2)(C_1 u_1^2 + C_2 u_2^2 + C_3 u_3^2)$, is convex on the control set U . Also we can see that there exist a constant $\rho > 1$ and positive numbers ω_1 and ω_2 such that

$$J(u_1, u_2, u_3) \geq \omega_1 (|u_1|^2 + |u_2|^2 + |u_3|^2)^{\rho/2} - \omega_2, \tag{14}$$

because the state variables are bounded, which complete the existence of an optimal control. $\square$

In order to derive the necessary conditions, we use Pontryagin's maximum principle [14] as follows. If (x, u) is an optimal solution of an optimal control problem, then

FIGURE 1: The plot represents the population of susceptible humans with and without control.

there exists a nontrivial vector function $\lambda = (\lambda_1, \lambda_2, \dots, \lambda_n)$ satisfying the following equations:

$$\begin{aligned}
\frac{dx}{dt} &= \frac{\partial H(t, x, u, \lambda)}{\partial \lambda}, & 0 &= \frac{\partial H(t, x, u, \lambda)}{\partial u}, \\
\frac{d\lambda}{dt} &= -\frac{\partial H(t, x, u, \lambda)}{\partial x}.
\end{aligned} \tag{15}$$

We now derive the necessary conditions that optimal control functions and corresponding states must satisfy. In the following theorem, we present the adjoint system and control characterization.

Theorem 2. *Let $X_h^*, E_h^*, I_h^*, T_h^*, R_h^*, X_b^*, E_b^*$, and I_b^* be optimal state solutions with associated optimal control variables*

$(u_1^*, u_2^*, \text{ and } u_3^*)$ for the optimal control problem (2)–(3). Then there exist adjoint variables λ_i , for $i = 1, 2, \dots, 8$, satisfying

$$\begin{aligned}\frac{d\lambda_1}{dt} &= (\lambda_1 - \lambda_2)(1 - u_1)(\alpha_1 I_h + \alpha_2 I_b) + \lambda_1 \mu_h, \\ \frac{d\lambda_2}{dt} &= (\lambda_2 - \lambda_3)\phi_h + \lambda_2 \mu_h, \\ \frac{d\lambda_3}{dt} &= (\lambda_1 - \lambda_2)(1 - u_1)\alpha_1 X_h + (\lambda_3 - \lambda_4)\rho_h \\ &\quad + \lambda_3(\beta_h + \mu_h + u_2) - \lambda_5 u_2 - A_1, \\ \frac{d\lambda_4}{dt} &= (\lambda_4 - \lambda_5)\gamma_h + \lambda_4 \mu_h, \\ \frac{d\lambda_5}{dt} &= (\lambda_5 - \lambda_1)\epsilon_h + \lambda_5 \mu_h, \\ \frac{d\lambda_6}{dt} &= (\lambda_6 - \lambda_7)(1 - u_3)\alpha_3 I_b + \lambda_6 \mu_b, \\ \frac{d\lambda_7}{dt} &= (\lambda_7 - \lambda_8)\phi_b + \lambda_7 \mu_b, \\ \frac{d\lambda_8}{dt} &= (\lambda_6 - \lambda_7)(1 - u_3)\alpha_3 X_b + \lambda_8(\beta_b + \mu_b) - A_2\end{aligned}\quad (16)$$

with transversality conditions

$$\lambda_i(t_{\text{end}}) = 0, \quad i = 1, 2, \dots, 8. \quad (17)$$

Furthermore the control functions u_1^* , u_2^* , and u_3^* are given by

$$\begin{aligned}u_1^* &= \max \left\{ \min \left\{ \frac{(\lambda_2 - \lambda_1)\alpha_1 X_h^* t_h^*}{c_1}, 1 \right\}, 0 \right\}, \\ u_2^* &= \max \left\{ \min \left\{ \frac{(\lambda_3 - \lambda_5)I_h^*}{c_2}, 1 \right\}, 0 \right\}, \\ u_3^* &= \max \left\{ \min \left\{ \frac{(\lambda_7 - \lambda_6)\alpha_3 X_b^* t_b^*}{c_3}, 1 \right\}, 0 \right\}.\end{aligned}\quad (18)$$

Proof. To determine the adjoint equations and the transversality conditions, we use the Hamiltonian H in (12). The adjoint system results from Pontryagin's maximum principle [14]:

$$\begin{aligned}\frac{d\lambda_1}{dt} &= -\frac{\partial H}{\partial X_h}, & \frac{d\lambda_2}{dt} &= -\frac{\partial H}{\partial E_h}, & \frac{d\lambda_3}{dt} &= -\frac{\partial H}{\partial I_h}, \\ \frac{d\lambda_4}{dt} &= -\frac{\partial H}{\partial T_h}, & \frac{d\lambda_5}{dt} &= -\frac{\partial H}{\partial R_h}, & \frac{d\lambda_6}{dt} &= -\frac{\partial H}{\partial X_b}, \\ \frac{d\lambda_7}{dt} &= -\frac{\partial H}{\partial E_b}, & \frac{d\lambda_8}{dt} &= -\frac{\partial H}{\partial I_b}\end{aligned}\quad (19)$$

with $\lambda_i(t_{\text{end}}) = 0, i = 1, 2, \dots, 8$.

To get the characterization of the optimal control given by (18), solving the equations

$$\frac{\partial H}{\partial u_1} = 0, \quad \frac{\partial H}{\partial u_2} = 0, \quad \frac{\partial H}{\partial u_3} = 0, \quad (20)$$

FIGURE 2: The plot represents the population of exposed humans with and without control.

FIGURE 3: The plot represents the population of infected humans with and without control.

on the interior of the control set, and setting the property of the control space U , we can derive the desired characterization (18). $\square$

4. Numerical Results and Discussion

In this section, we present a semi-implicit finite difference method by discretizing the interval $[t_0, t_f]$ at the points $t_i = t_0 + il$, ($i = 0, 1, \dots, n$), where l represents the time step such that $t_n = t_f$. We define the state and adjoint variables $X_h, E_h,$

FIGURE 4: The plot represents the population of treated humans with and without control.

$I_h, T_h, R_h, X_b, E_b, I_b, \lambda_1, \lambda_2, \lambda_3, \lambda_4, \lambda_5, \lambda_6, \lambda_7$, and λ_8 and the controls u_1, u_2 , and u_3 in terms of nodal points $X_h^i, E_h^i, I_h^i, T_h^i, R_h^i, X_b^i, E_b^i, I_b^i, \lambda_1^i, \lambda_2^i, \lambda_3^i, \lambda_4^i, \lambda_5^i, \lambda_6^i, \lambda_7^i, \lambda_8^i, u_1^i, u_2^i$, and u_3^i . By combination of forward and backward difference approximation, the method developed by [19] to adopt it in our case is given by

$$\begin{aligned}
 \frac{X_h^{i+1} - X_h^i}{l} &= \Lambda - \mu_h X_h^{i+1} - (1 - u_1^i) \alpha_1 X_h^{i+1} I_h^i \\
 &\quad - \alpha_2 X_h^{i+1} I_b^i + \epsilon_h R_h^i, \\
 \frac{E_h^{i+1} - E_h^i}{l} &= (1 - u_1^i) \alpha_1 X_h^{i+1} I_h^i + \alpha_2 X_h^{i+1} I_b^i \\
 &\quad - (\mu_h + \phi_h) E_h^{i+1}, \\
 \frac{I_h^{i+1} - I_h^i}{l} &= \phi_h E_h^{i+1} - (\rho_h + \beta_h + \mu_h + u_2^i) I_h^{i+1}, \\
 \frac{T_h^{i+1} - T_h^i}{l} &= \rho_h I_h^{i+1} - (\gamma_h + \mu_h) T_h^{i+1}, \\
 \frac{R_h^{i+1} - R_h^i}{l} &= \gamma_h T_h^{i+1} + u_2^i I_h^{i+1} - (\mu_h + \epsilon_h) R_h^{i+1}, \\
 \frac{X_b^{i+1} - X_b^i}{l} &= \pi - \mu_b X_b^{i+1} - (1 - u_3^i) \alpha_3 X_b^{i+1} I_b^i, \\
 \frac{E_b^{i+1} - E_b^i}{l} &= (1 - u_3^i) \alpha_3 X_b^{i+1} I_b^i - (\mu_b + \phi_b) E_b^{i+1}, \\
 \frac{I_b^{i+1} - I_b^i}{l} &= \phi_b E_b^{i+1} - (\beta_b + \mu_b) I_b^{i+1}.
 \end{aligned} \tag{21}$$

To approximate the time derivative of the adjoint variables by the first-ordered backward difference, we use the appropriate scheme as follows:

$$\begin{aligned}
 \frac{\lambda_1^{n-i} - \lambda_1^{n-i-1}}{l} &= (\lambda_1^{n-i-1} - \lambda_2^{n-i}) (1 - u_1^i) (\alpha_1 I_h^{i+1} + \alpha_2 I_b^{i+1}) \\
 &\quad + \lambda_1^{n-i-1} \mu_h, \\
 \frac{\lambda_2^{n-i} - \lambda_2^{n-i-1}}{l} &= (\lambda_2^{n-i-1} - \lambda_3^{n-i}) \phi_h + \lambda_2^{n-i-1} \mu_h, \\
 \frac{\lambda_3^{n-i} - \lambda_3^{n-i-1}}{l} &= (\lambda_1^{n-i-1} - \lambda_2^{n-i-1}) (1 - u_1^i) \alpha_1 X_h^{i+1} \\
 &\quad + \lambda_3^{n-i-1} (\rho_h + \beta_h + \mu_h + u_2^i) \\
 &\quad - \lambda_5^{n-i} u_2^i - \lambda_4^{n-i} \rho_h - A_1, \\
 \frac{\lambda_4^{n-i} - \lambda_4^{n-i-1}}{l} &= (\lambda_4^{n-i-1} - \lambda_5^{n-i}) \gamma_h + \lambda_4^{n-i-1} \mu_h, \\
 \frac{\lambda_5^{n-i} - \lambda_5^{n-i-1}}{l} &= (\lambda_5^{n-i-1} - \lambda_1^{n-i-1}) \epsilon_h + \lambda_5^{n-i-1} \mu_h, \\
 \frac{\lambda_6^{n-i} - \lambda_6^{n-i-1}}{l} &= (\lambda_6^{n-i-1} - \lambda_7^{n-i}) (1 - u_3^i) \alpha_3 I_b^{i+1} + \lambda_6^{n-i-1} \mu_b, \\
 \frac{\lambda_7^{n-i} - \lambda_7^{n-i-1}}{l} &= (\lambda_7^{n-i-1} - \lambda_8^{n-i}) \phi_b + \lambda_7^{n-i-1} \mu_b, \\
 \frac{\lambda_8^{n-i} - \lambda_8^{n-i-1}}{l} &= (\lambda_6^{n-i-1} - \lambda_7^{n-i-1}) (1 - u_3^i) \alpha_3 X_b^{i+1} \\
 &\quad + \lambda_8^{n-i-1} (\beta_b + \mu_b) - A_2.
 \end{aligned} \tag{22}$$

The algorithm that describes the approximation method for obtaining the optimal control is as follows.

Algorithm 3. Consider the following.

Step 1. Consider $X_h(0) = X_{h0}, E_h(0) = E_{h0}, I_h(0) = I_{h0}, T_h(0) = T_{h0}, R_h(0) = R_{h0}, X_b(0) = X_{b0}, E_b(0) = E_{b0}, I_b(0) = I_{b0}, u_1(0) = u_2(0) = u_3(0) = 0$, and $\lambda_i(t_f) = 0, i = 1, \dots, 8$.

Step 2. For $i = 1, \dots, n-1$, do

$$\begin{aligned}
 X_h^{i+1} &= \frac{X_h^i + l [\Lambda + \epsilon_h R_h^i]}{1 + l [\mu_h + (1 - u_1^i) \alpha_1 I_h^i + \alpha_2 I_b^i]}, \\
 E_h^{i+1} &= \frac{E_h^i + l [(1 - u_1^i) \alpha_1 X_h^{i+1} I_h^i + \alpha_2 X_h^{i+1} I_b^i]}{1 + l [\mu_h + \phi_h]}, \\
 I_h^{i+1} &= \frac{I_h^i + l \phi_h E_h^{i+1}}{1 + l [\rho_h + \beta_h + \mu_h + u_2^i]}, \\
 T_h^{i+1} &= \frac{T_h^i + l \rho_h I_h^{i+1}}{1 + l [\gamma_h + \mu_h]},
 \end{aligned}$$

FIGURE 5: The plot represents the population of recovered humans with and without control.

$$\begin{aligned}
 R_h^{i+1} &= \frac{R_h^i + l [\gamma T_h^{i+1} + u_2^i I_h^{i+1}]}{1 + l [\mu_h + \epsilon_h]}, \\
 X_b^{i+1} &= \frac{X_b^i + l \pi}{1 + l [\mu_b + (1 - u_3^i) \alpha_3 I_b^i]}, \\
 E_b^{i+1} &= \frac{E_b^i + l (1 - u_3^i) \alpha_3 X_b^{i+1} I_b^i}{1 + l [\mu_b + \phi_b]}, \\
 I_b^{i+1} &= \frac{I_b^i + l \phi_b E_b^{i+1}}{1 + l [\beta_b + \mu_b]}, \\
 \lambda_1^{n-i-1} &= \frac{\lambda_1^{n-i} + l \lambda_2^{n-i} (1 - u_1^i) [\alpha_1 I_h^{i+1} + \alpha_2 I_h^{i+1}]}{1 + l [(1 - u_1^i) \alpha_1 I_h^{i+1} + \alpha_2 I_h^{i+1} + \mu_h]}, \\
 \lambda_2^{n-i-1} &= \frac{\lambda_3^{n-i} + l \lambda_3^{n-i} \phi_h}{1 + l \lambda_2^{n-i-1} [\phi_h + \mu_h]}, \\
 \lambda_3^{n-i-1} &= \lambda_3^{n-i} + l [(\lambda_2^{n-i-1} - \lambda_1^{n-i-1}) (1 - u_1^i) \alpha_1 X_h^{i+1} \\
 &\quad + \rho_h \lambda_4^{n-i} + u_2^i \lambda_5^{n-i} + A_1] \\
 &\quad \times (1 + l [\rho_h + \beta_h + \mu_h + u_2^i])^{-1}, \\
 \lambda_4^{n-i-1} &= \frac{\lambda_4^{n-i} - l \gamma_h \lambda^{n-i}}{1 - l [\gamma_h + \mu_h]}, \\
 \lambda_5^{n-i-1} &= \frac{\lambda_5^{n-i} + l \epsilon_h \lambda_1^{n-i-1}}{1 + l [\epsilon_h + \mu_h]}, \\
 \lambda_6^{n-i-1} &= \frac{\lambda_6^{n-i} + l (1 - u_3^i) I_b^{i+1} \lambda_7^{n-i}}{1 + l [\mu_b + (1 - u_3^i) \alpha_3 I_b^{i+1}]},
 \end{aligned}$$

$$\begin{aligned}
 \lambda_7^{n-i-1} &= \frac{\lambda_7^{n-i} + l \phi_b \lambda_8^{n-i}}{1 + l [\phi_b + \mu_b]}, \\
 \lambda_8^{n-i-1} &= \frac{\lambda_8^{n-i} + l [(\lambda_7^{n-i-1} - \lambda_6^{n-i-1}) (1 - u_3^i) \alpha_3 X_b^{i+1} + A_2]}{1 + l [\beta_b + \mu_b]}, \\
 u_1^{i+1} &= \max \left\{ \min \left\{ \frac{(\lambda_2^{n-i-1} - \lambda_1^{n-i-1}) \alpha_1 X_h^{i+1} I_h^{i+1}}{c_1}, 1 \right\}, 0 \right\}, \\
 u_2^{i+1} &= \max \left\{ \min \left\{ \frac{(\lambda_3^{n-i-1} - \lambda_5^{n-i-1}) I_b^{i+1}}{c_2}, 1 \right\}, 0 \right\}, \\
 u_3^{i+1} &= \max \left\{ \min \left\{ \frac{(\lambda_7^{n-i-1} - \lambda_6^{n-i-1}) \alpha_3 X_b^{i+1} I_b^{i+1}}{c_3}, 1 \right\}, 0 \right\},
 \end{aligned} \tag{23}$$

end for.

Step 3. For $i = 1, \dots, n-1$, write $X_h^*(t_i) = X_h^i$, $E_h^*(t_i) = E_h^i$, $I_h^*(t_i) = I_h^i$, $T_h^*(t_i) = T_h^i$, $R_h^*(t_i) = R_h^i$, $X_b^*(t_i) = X_b^i$, $E_b^*(t_i) = E_b^i$, $I_b^*(t_i) = I_b^i$, $u_1^*(t_i) = u_1^i$, $u_2^*(t_i) = u_2^i$, and $u_3^*(t_i) = u_3^i$ end for.

We have plotted susceptible, exposed, infected, treated, and recovered population of humans and susceptible, exposed, and infected population of birds with and without control by considering parameter values given in Table 1, with initial values $X_h(0) = 40$, $E_h(0) = 20$, $I_h(0) = 10$, $T_h(0) = 8$, $R_h(0) = 5$, $X_b(0) = 70$, $E_b(0) = 30$, and $I_b(0) = 20$. In each of the given figures the undashed and the dashed lines represent the individuals without and with control, respectively. The weight constant of the objective functional $A_1 = 0.035$, $A_2 = 0.0015$, $C_1 = 0.05$, $C_2 = 0.08$, and $C_3 = 0.002$ is considered for numerical simulation. Figure 1 shows that the population of the susceptible humans increased after control, in Figures 2 and 3 we see that the number of the exposed and infected humans with control decreased more sharply than that without control, Figure 4 shows that per day clinically reported humans decreased after control, Figure 5 shows that the number of recovered human individuals increased after control, Figure 6 shows that the birds population increased after control, and in Figures 7 and 8 we see that the number of the exposed and infected birds decreased after control. Figure 9 shows the graphs of control variables.

5. Conclusion

An optimal control problem of the transmission dynamics of the human-avian influenza disease has been presented. We sought to determine three types of control functions associated with isolation and antiviral treatment of the clinically infectious individuals and elimination of the infected birds. Our control plots indicated that the number of exposed, infected, and hospitalized humans and the number of exposed, infected birds decreased in the optimal system. We developed the necessary conditions for the existence of the optimal control by using Pontryagin's maximum

FIGURE 6: The plot represents the population of susceptible birds with and without control.

FIGURE 8: The plot represents the population of infected birds with and without control.

FIGURE 7: The plot represents the population of exposed birds with and without control.

FIGURE 9: The plot represents the control variables u_1 , u_2 , and u_3 .

principle. Using the state and adjoint system together with the characterization of the optimal control, we solved the problem numerically by an efficient numerical method based on optimal control with the estimated parameter values based on avian influenza. The results show that the control practices are very effective in reducing the incidence of infectious population.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

- [1] Centers for Disease Control and Prevention, "Key Facts about Avian Influenza (Bird Flu) and Avian Influenza A, (H5N1) Virus," 2006, <http://www.cdc.gov/flu/avian/gen-info/facts.htm>.

- [2] M. Martcheva, B. M. Bolker, and R. D. Holt, "Vaccine-induced pathogen strain replacement: what are the mechanisms?" *Journal of the Royal Society Interface*, vol. 5, no. 18, pp. 3–13, 2008.
- [3] Y. Yang, M. E. Halloran, J. D. Sugimoto, and I. M. Longini Jr., "Detecting human-to-human transmission of avian influenza A (H5N1)," *Emerging Infectious Diseases*, vol. 13, no. 9, pp. 1348–1353, 2007.
- [4] M. Zaman, S. Ashraf, N. A. Dreyer, and S. Toovey, "Human infection with avian influenza virus, Pakistan, 2007," *Emerging Infectious Diseases*, vol. 17, no. 6, pp. 1056–1059, 2011.
- [5] World Health Organization Europe, "Making preparation count: lessons from the avian influenza outbreak in Turkey," 2006, http://www.euro.who.int/_data/assets/pdf.file/0018/90513/E89139.pdf.
- [6] D. Butler, "Family tragedy spotlights flu mutations," *Nature*, vol. 442, no. 7099, pp. 114–115, 2006.
- [7] N. M. Ferguson, D. A. T. Cummings, S. Cauchemez et al., "Strategies for containing an emerging influenza pandemic in southeast Asia," *Nature*, vol. 437, no. 7056, pp. 209–214, 2005.
- [8] R. F. Grais, J. H. Ellis, and G. E. Glass, "Assessing the impact of airline travel on the geographic spread of pandemic influenza," *European Journal of Epidemiology*, vol. 18, no. 11, pp. 1065–1072, 2003.
- [9] I. M. Longini Jr., A. Nizam, S. Xu et al., "Containing pandemic influenza at the source," *Science*, vol. 309, no. 5737, pp. 1083–1087, 2005.
- [10] S. Iwami, Y. Takeuchi, and X. Liu, "Avian-human influenza epidemic model," *Mathematical Biosciences*, vol. 207, no. 1, pp. 1–25, 2007.
- [11] S. Lee, G. Chowell, and C. Castillo-Chávez, "Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation," *Journal of Theoretical Biology*, vol. 265, no. 2, pp. 136–150, 2010.
- [12] R. Ullah, G. Zaman, and S. Islam, "Prevention of influenza pandemic by multiple control strategies," *Journal of Applied Mathematics*, vol. 2012, Article ID 294275, 14 pages, 2012.
- [13] R. Ullah, G. Zaman, S. Islam, and M. R. Muhyuddin, "Global dynamics of the avian-human influenza with horizontal transmission in human population," *Life Science Journal*, vol. 9, no. 4, pp. 5747–5753, 2012.
- [14] L. S. Pontryagin, V. G. Boltyanskii, R. V. Gamkrelidze, and E. F. Mishchenko, *The Mathematical Theory of Optimal Processes*, John Wiley & Sons, Hoboken, NJ, USA, 1962.
- [15] G. Birkhoff and G. C. Rotta, *Ordinary Differential Equations*, John Wiley & Sons, New York, NY, USA, 4th edition, 1989.
- [16] A. A. Lashari and G. Zaman, "Optimal control of a vector borne disease with horizontal transmission," *Nonlinear Analysis: Real World Applications*, vol. 13, no. 1, pp. 203–212, 2012.
- [17] D. L. Lukes, *Differential Equations: Classical to Controlled*, vol. 162 of *Mathematics in Science and Engineering*, Academic Press, New York, NY, USA, 1982.
- [18] G. Zaman, Y. Han Kang, and I. H. Jung, "Stability analysis and optimal vaccination of an SIR epidemic model," *BioSystems*, vol. 93, no. 3, pp. 240–249, 2008.
- [19] A. B. Gumel, P. N. Shivakumar, and B. M. Sahai, "A mathematical model for the dynamics of HIV-1 during the typical course of infection," in *Proceedings of the 3rd World Congress of Non-linear Analysts*, vol. 47, pp. 2073–2083, 2001.